Journal of Neuropathology & Experimental Neurology
·
December 23, 2024
Fostering Collaboration to
Accelerate
Discoveries 
A premier center for genomic research, the New York Genome Center (NYGC) fosters collaboration among leading scientists from multiple institutions to accelerate genomic discoveries and their translation into new therapies and diagnostics.
In Memoriam:
Dr. Thomas Lehner,
Pioneer in Neuropsychiatric Disease Research
August 29, 1960 – November 6, 2024
Dr. Lehner was a visionary in the field of neuropsychiatric disease research. A champion of open science and collaboration, Dr. Lehner was a respected leader in the study of the genetic underpinnings of neuropsychiatric disorders such as, schizophrenia, bipolar disorder, autism, and Alzheimer’s disease. His legacy of scientific innovation and collaboration will continue to inspire generations to come.
Latest News & Publications
Research Sequencing 
Neuropsychiatric Disease 
NYGC at a Glance
- 13 Founding and Associate Institutional Members
- 4 NIH Innovator Awards
- 10 Core Faculty
- 10 Associate Faculty
- 148K+ Whole Genome Equivalents Sequenced
- 93 Affiliated Scientists Across 18 Institutions
-
$143M
Grants Under Management*
*as of 12/2023
Shared Stories of Success
The NYGC has built a unique scientific ecosystem for multi-institutional collaborations in genomic research. Leveraging our strengths and expertise in collaboration, sequencing at scale, genomic analysis, and technology development, we advance novel approaches and partnerships beyond that possible for any single institution to gain insights into the biological drivers and molecular mechanisms of disease, with the goal of advancing the practice of precision medicine.”
Tom Maniatis, PhD Evnin Family Scientific Director & CEO
Isidore S. Edelman Professor of Biochemistry and Molecular Biophysics, Columbia University
Studying the changes in gene expression we see in each stage of ALS is key to identifying what triggers symptom onset. Our work with Target ALS ensures we maintain productive collaborations with ALS researchers to develop life-changing treatments.”
Read more on NYGC’s work with Target ALS and New York State.
Hemali Phatnani Director, Center for Genomics of Neurodegenerative Disease, NYGC
Assistant Professor of Neurological Sciences (in Neurology), Columbia University
The ability to leverage data generated in a different lab and even processed with a different method, to then use it to link individuals in a completely different anonymous dataset, is rather striking and highlights a real privacy issue for single-cell data. We aim for this study to help quantify risks before data release and shape the design of future studies to ensure greater privacy for patients.”
Gamze Gürsoy, PhD Core Faculty Member, NYGC
Herbert Irving Assistant Professor of Biomedical Informatics, Columbia University
Decoding causality is fundamental to providing interpretable quantitative explanations of elements of the non-coding genome in cancer. Biological problems of this nature require cross-cutting programs where investigators with a broad range of expertise are supported to collaborate and focus on building new measurement methods and computational frameworks to understand the complex dynamics of cancer biology.”
Samuel Aparicio, BM, BCh, PhD, FRCPath, FRSC Senior Scientific Director of Cancer Genomics, NYGC
Chair of Molecular Oncology, UBC/BC Cancer Agency
Collaborative Research Programs
Groundbreaking Research
We cultivate a diverse research community dedicated to advancing the understanding of genomic science and the treatment of human disease.
Cancer Research 
Neurodegenerative Disease Research 
Neuropsychiatric Disease Research 
Biology, Genomics & Technology 
Scientific Collaboration & Project Management 
Technology Platforms
Innovative Technology Platforms
Our multidisciplinary team of scientists, engineers, and NYGC faculty come together to explore and test innovative genomic tools and technologies to drive progress within our center and the broader scientific community.
Technology Innovation 
Technology Development 
Research Sequencing 
Computational Biology Lab 
Clinical Genetics
The New York Genome Center has a state-of-the-art clinical diagnostic laboratory that utilizes next-generation sequencing technology to perform cutting-edge tests in the areas of genetics and oncology. The Clinical Laboratory is accredited by the Clinical Laboratory Improvement Amendments (CLIA) and the Clinical Laboratory Evaluation Program of the New York State Department of Health (CLEP). It is licensed to perform clinical testing in all fifty (50) of the United States and the District of Columbia. The laboratory participates in the College of American Pathologists (CAP) proficiency testing.
Celebrating Diverse Perspectives
At the NYGC, we’re committed to building a diverse, equitable, and inclusive workplace culture where everyone can contribute to our mission of advancing genomic research.
